Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: Navane
Published 2026-02-15 · Last reviewed 2026-02-22 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Thiothixene is a high-potency FGA (thioxanthene) used for schizophrenia. It is an oral-only medication with no LAI formulation (label/clinical).
Compared with low-potency phenothiazines, thiothixene is generally less sedating and less anticholinergic, but movement-disorder risk (EPS and tardive dyskinesia) is often more prominent and can be the limiting factor (label/clinical).
Many clinicians consider it mainly for cost-sensitive maintenance in stable patients who have previously tolerated FGAs; it is less commonly chosen for first-episode care due to tolerability and adherence considerations (AHRQ/clinical).
Early follow-up often focuses on akathisia (inner restlessness) because it can be mistaken for anxiety or agitation and can drive nonadherence if not recognized (clinical).
The thiothixene compare view, evidence feed, and print page help compare EPS, sedation, and metabolic trade-offs.
Thiothixene is an older, inexpensive oral antipsychotic. Its role is often constrained by movement-disorder risk and lack of a depot formulation, especially when adherence concerns are prominent (AHRQ/clinical).
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Dopamine D2 receptor antagonism is the primary antipsychotic mechanism.
Relative “high potency” is associated with higher EPS risk at clinical doses.